Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 13
mi
from
Atlanta, GA
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 13
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 19
mi
from
Boise, ID
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 19
mi
from
Boise, ID
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 04
mi
from
Rockville, MD
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 04
mi
from
Rockville, MD
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 4
mi
from
Ann Arbor, MI
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 4
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 09
mi
from
Clarkston, MI
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 09
mi
from
Clarkston, MI
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 15
mi
from
Las Vegas, NV
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 15
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 9
mi
from
Raleigh, NC
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 9
mi
from
Raleigh, NC
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 7
mi
from
Knoxville, TN
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 7
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 05
mi
from
Austin, TX
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 05
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 10
mi
from
San Antonio, TX
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 10
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 15
mi
from
Spokane, WA
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 15
mi
from
Spokane, WA
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 14
mi
from
Santa Ana, CA
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 14
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 3
mi
from
Boynton Beach, FL
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 3
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 10
mi
from
Clearwater, FL
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 10
mi
from
Clearwater, FL
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 2
mi
from
Tampa, FL
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 2
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 05
mi
from
Plainfield, IN
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 05
mi
from
Plainfield, IN
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 12
mi
from
Olathe, KA
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 12
mi
from
Olathe, KA
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 07
mi
from
Fridley, MN
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 07
mi
from
Fridley, MN
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 31
mi
from
Omaha, NE
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 31
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 03
mi
from
New York, NY
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 03
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 31
mi
from
Stony Brook, NY
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 31
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 02
mi
from
High Point, NC
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 02
mi
from
High Point, NC
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 7
mi
from
Knoxville, TN
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 7
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 01
mi
from
Houston, TX
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 01
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 10
mi
from
San Antonio, TX
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 10
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  2/13/2018
Valeant Site 06
mi
from
West Jordan, UT
Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 2/13/2018
Valeant Site 06
mi
from
West Jordan, UT
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated:  2/14/2018
Novartis Investigative Site
mi
from
Phoenix, AZ
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated: 2/14/2018
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated:  2/14/2018
Novartis Investigative Site
mi
from
Skokie, IL
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated: 2/14/2018
Novartis Investigative Site
mi
from
Skokie, IL
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated:  2/14/2018
Novartis Investigative Site
mi
from
Indianapolis, IN
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated: 2/14/2018
Novartis Investigative Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated:  2/14/2018
Novartis Investigative Site
mi
from
High Point, NC
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated: 2/14/2018
Novartis Investigative Site
mi
from
High Point, NC
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated:  2/14/2018
Novartis
mi
from
Portland, OR
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated: 2/14/2018
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated:  2/14/2018
Novartis Investigative Site
mi
from
Duncansville, PA
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated: 2/14/2018
Novartis Investigative Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated:  2/14/2018
Novartis Investigative Site
mi
from
Nashville, TN
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated: 2/14/2018
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated:  2/14/2018
Novartis Investigative Site
mi
from
Houston, TX
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated: 2/14/2018
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated:  2/14/2018
Novartis Investigator Site
mi
from
Birmingham, AL
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated: 2/14/2018
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated:  2/14/2018
Novartis Investigative Site
mi
from
Sydney,
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis
Status: Enrolling
Updated: 2/14/2018
Novartis Investigative Site
mi
from
Sydney,
Click here to add this to my saved trials
Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Randomized Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis Who Have Sub-optimal Response to Prior Therapy
Status: Enrolling
Updated:  2/15/2018
Rockefeller University
mi
from
New York, NY
Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Randomized Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis Who Have Sub-optimal Response to Prior Therapy
Status: Enrolling
Updated: 2/15/2018
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
Forward Clinical Trials
mi
from
Tampa, FL
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
Forward Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
Northwestern University
mi
from
Chicago, IL
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
Icahn School of Medicine
mi
from
New York, NY
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
Icahn School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
Menter Dermatology Research Institute
mi
from
Dallas, TX
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
Menter Dermatology Research Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
Center for Clinical Studies
mi
from
Houston, TX
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
Center for Clinical Studies
mi
from
Houston, TX
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
Center for Clinical Studies
mi
from
Webster, TX
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
Center for Clinical Studies
mi
from
Webster, TX
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
Oregon Health and Science University
mi
from
Portland, OR
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
Dermatology Research Associates
mi
from
Los Angeles, CA
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
Dermatology Research Associates
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
Medical Dermatology Specialists
mi
from
Atlanta, GA
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
Medical Dermatology Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  2/16/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Fukuoka-shi,
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 2/16/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Fukuoka-shi,
Click here to add this to my saved trials
BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
A Randomized, Double-Blind Study Comparing TOLMAR Calcipotriene and Betamethasone Suspension to Reference Listed Drug in the Treatment of Scalp Psoriasis
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Hot Springs, AR
BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
A Randomized, Double-Blind Study Comparing TOLMAR Calcipotriene and Betamethasone Suspension to Reference Listed Drug in the Treatment of Scalp Psoriasis
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Hot Springs, AR
Click here to add this to my saved trials
BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
A Randomized, Double-Blind Study Comparing TOLMAR Calcipotriene and Betamethasone Suspension to Reference Listed Drug in the Treatment of Scalp Psoriasis
Status: Enrolling
Updated:  3/5/2018
Clinical Research Facility
mi
from
Fremont, CA
BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
A Randomized, Double-Blind Study Comparing TOLMAR Calcipotriene and Betamethasone Suspension to Reference Listed Drug in the Treatment of Scalp Psoriasis
Status: Enrolling
Updated: 3/5/2018
Clinical Research Facility
mi
from
Fremont, CA
Click here to add this to my saved trials